INS and Parkinson disease: Similarly, in rodents, insulin secretory response is inhibited by a single injection with the dopamine precursor L-dopa (77, 78), whereas reduced insulin secretion upon a glucose load has been reported in humans with Parkinson’s disease treated with L-dopa (79).